uniQure (NASDAQ:QURE) Trading Up 9.1% – Time to Buy?

uniQure N.V. (NASDAQ:QURE) shares traded up 9.1% during trading on Monday . The company traded as high as $18.80 and last traded at $19.1740. 841,828 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 3,014,750 shares. The stock had previously closed at $17.58.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on QURE shares. Chardan Capital lifted their price objective on uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Wolfe Research began coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. Stifel Nicolaus set a $14.00 price target on shares of uniQure in a report on Monday, March 2nd. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Finally, Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Stock Performance

The stock has a market cap of $1.11 billion, a P/E ratio of -5.15 and a beta of 0.75. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average price of $17.37 and a two-hundred day moving average price of $27.58.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. On average, sell-side analysts forecast that uniQure N.V. will post -3.6 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the transaction, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the sale, the chief financial officer owned 226,581 shares in the company, valued at approximately $2,052,823.86. This represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 49,396 shares of company stock worth $722,734 over the last quarter. Insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Hedge funds have recently made changes to their positions in the company. Avoro Capital Advisors LLC grew its holdings in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the last quarter. State Street Corp raised its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of uniQure by 23.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after acquiring an additional 383,066 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.